BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis
FRA:BRM • US1101221083
50.38 EUR
-0.18 (-0.36%)
Last: Feb 18, 2026, 07:00 PM
We assign a fundamental rating of 5 out of 10 to BRM. BRM was compared to 52 industry peers in the Pharmaceuticals industry. BRM has only an average score on both its financial health and profitability. BRM is valued quite cheap, but it does not seem to be growing. Finally BRM also has an excellent dividend rating. These ratings could make BRM a good candidate for value and dividend investing.
1. Profitability
1.1 Basic Checks
- BRM had positive earnings in the past year.
- In the past year BRM had a positive cash flow from operations.
- Of the past 5 years BRM 4 years were profitable.
- BRM had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- The Return On Assets of BRM (6.23%) is comparable to the rest of the industry.
- With an excellent Return On Equity value of 32.55%, BRM belongs to the best of the industry, outperforming 80.77% of the companies in the same industry.
- Looking at the Return On Invested Capital, with a value of 17.64%, BRM is in the better half of the industry, outperforming 73.08% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROIC | 17.64% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of BRM (12.57%) is comparable to the rest of the industry.
- In the last couple of years the Profit Margin of BRM has grown nicely.
- BRM has a better Operating Margin (33.51%) than 82.69% of its industry peers.
- In the last couple of years the Operating Margin of BRM has grown nicely.
- BRM has a Gross Margin (73.15%) which is in line with its industry peers.
- BRM's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% |
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BRM is creating value.
- BRM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 2.32 indicates that BRM is not a great score, but indicates only limited risk for bankruptcy at the moment.
- The Altman-Z score of BRM (2.32) is comparable to the rest of the industry.
- The Debt to FCF ratio of BRM is 3.20, which is a good value as it means it would take BRM, 3.20 years of fcf income to pay off all of its debts.
- BRM has a better Debt to FCF ratio (3.20) than 67.31% of its industry peers.
- BRM has a Debt/Equity ratio of 2.41. This is a high value indicating a heavy dependency on external financing.
- BRM's Debt to Equity ratio of 2.41 is on the low side compared to the rest of the industry. BRM is outperformed by 80.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Altman-Z | 2.32 |
ROIC/WACC2.06
WACC8.55%
2.3 Liquidity
- A Current Ratio of 1.27 indicates that BRM should not have too much problems paying its short term obligations.
- Looking at the Current ratio, with a value of 1.27, BRM is in line with its industry, outperforming 40.38% of the companies in the same industry.
- BRM has a Quick Ratio of 1.17. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 1.17, BRM is in the better half of the industry, outperforming 69.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 439.47% over the past year.
- Measured over the past years, BRM shows a decrease in Earnings Per Share. The EPS has been decreasing by -0.92% on average per year.
- The Revenue has decreased by -0.22% in the past year.
- The Revenue has been growing slightly by 2.54% on average over the past years.
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%
3.2 Future
- BRM is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -4.54% yearly.
- The Revenue is expected to decrease by -5.61% on average over the next years.
EPS Next Y-1.05%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
EPS Next 5Y-4.54%
Revenue Next Year-7.97%
Revenue Next 2Y-5.07%
Revenue Next 3Y-5.93%
Revenue Next 5Y-5.61%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- BRM is valuated reasonably with a Price/Earnings ratio of 9.69.
- BRM's Price/Earnings ratio is rather cheap when compared to the industry. BRM is cheaper than 90.38% of the companies in the same industry.
- BRM is valuated cheaply when we compare the Price/Earnings ratio to 27.27, which is the current average of the S&P500 Index.
- BRM is valuated reasonably with a Price/Forward Earnings ratio of 9.79.
- 84.62% of the companies in the same industry are more expensive than BRM, based on the Price/Forward Earnings ratio.
- BRM is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.16, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.69 | ||
| Fwd PE | 9.79 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, BRM is valued cheaper than 92.31% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, BRM is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.93 | ||
| EV/EBITDA | 7.29 |
4.3 Compensation for Growth
- BRM has a very decent profitability rating, which may justify a higher PE ratio.
- A cheap valuation may be justified as BRM's earnings are expected to decrease with -3.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 4.21%, BRM is a good candidate for dividend investing.
- BRM's Dividend Yield is rather good when compared to the industry average which is at 1.91. BRM pays more dividend than 84.62% of the companies in the same industry.
- BRM's Dividend Yield is rather good when compared to the S&P500 average which is at 1.84.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.21% |
5.2 History
- On average, the dividend of BRM grows each year by 11.67%, which is quite nice.
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
- 82.81% of the earnings are spent on dividend by BRM. This is not a sustainable payout ratio.
- The Dividend Rate of BRM has been growing, while earnings will be declining. This means the dividend growth is most likely not sustainable.
DP82.81%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
FRA:BRM (2/18/2026, 7:00:00 PM)
50.38
-0.18 (-0.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05 2026-02-05/bmo
Earnings (Next)04-30 2026-04-30
Inst Owners81.87%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap102.56B
Revenue(TTM)48.19B
Net Income(TTM)6.04B
Analysts70.59
Price Target48.84 (-3.06%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.21% |
Yearly Dividend2.04
Dividend Growth(5Y)11.67%
DP82.81%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.98%
Min EPS beat(2)6.92%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.52%
EPS beat(12)11
Avg EPS beat(12)11.66%
EPS beat(16)15
Avg EPS beat(16)10.13%
Revenue beat(2)2
Avg Revenue beat(2)4.61%
Min Revenue beat(2)2.43%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)4.63%
Min Revenue beat(4)2.43%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.95%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)11
Avg Revenue beat(16)1.64%
PT rev (1m)3.55%
PT rev (3m)7.06%
EPS NQ rev (1m)-29.59%
EPS NQ rev (3m)-32.32%
EPS NY rev (1m)0.39%
EPS NY rev (3m)-0.06%
Revenue NQ rev (1m)0.44%
Revenue NQ rev (3m)0.02%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)0.77%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.69 | ||
| Fwd PE | 9.79 | ||
| P/S | 2.53 | ||
| P/FCF | 7.93 | ||
| P/OCF | 7.3 | ||
| P/B | 6.54 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.29 |
EPS(TTM)5.2
EY10.32%
EPS(NY)5.15
Fwd EY10.21%
FCF(TTM)6.36
FCFY12.62%
OCF(TTM)6.9
OCFY13.7%
SpS19.95
BVpS7.71
TBVpS-9.83
PEG (NY)N/A
PEG (5Y)N/A
Graham Number30.03
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROCE | 23.41% | ||
| ROIC | 17.64% | ||
| ROICexc | 23.19% | ||
| ROICexgc | 118.19% | ||
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% | ||
| FCFM | 31.86% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
F-Score6
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Debt/EBITDA | 2.13 | ||
| Cap/Depr | 26.84% | ||
| Cap/Sales | 2.75% | ||
| Interest Coverage | 7.66 | ||
| Cash Conversion | 79.11% | ||
| Profit Quality | 253.39% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 2.32 |
F-Score6
WACC8.55%
ROIC/WACC2.06
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
EPS Next Y-1.05%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
EPS Next 5Y-4.54%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%
Revenue Next Year-7.97%
Revenue Next 2Y-5.07%
Revenue Next 3Y-5.93%
Revenue Next 5Y-5.61%
EBIT growth 1Y44.7%
EBIT growth 3Y14.87%
EBIT growth 5Y23.65%
EBIT Next Year13.96%
EBIT Next 3Y0.03%
EBIT Next 5Y-1.73%
FCF growth 1Y10.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.78%
OCF growth 3YN/A
OCF growth 5YN/A
BRISTOL-MYERS SQUIBB CO / BRM.DE FAQ
What is the fundamental rating for BRM stock?
ChartMill assigns a fundamental rating of 5 / 10 to BRM.DE.
What is the valuation status of BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
ChartMill assigns a valuation rating of 7 / 10 to BRISTOL-MYERS SQUIBB CO (BRM.DE). This can be considered as Undervalued.
How profitable is BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a profitability rating of 6 / 10.
What is the expected EPS growth for BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BRM.DE) is expected to decline by -1.05% in the next year.
Is the dividend of BRISTOL-MYERS SQUIBB CO sustainable?
The dividend rating of BRISTOL-MYERS SQUIBB CO (BRM.DE) is 7 / 10 and the dividend payout ratio is 82.81%.